Sabinsa cosmetics

Sabinsa’s Curcumin C3 Complex®, the #1 clinically studied curcumin brand on the market, is the subject of a recently published study on its effect, combined with BioPerine®, on serum cytokine concentrations. Effects of supplementation with curcuminoids on serum adipokines in critically ill patients: a randomized double-blind placebo-controlled trial was published in the peer-reviewed journal Phytotherapy Research.

Sabinsa cosmetics

Sabinsa founder and chairman Dr. Muhammed Majeed presents check to PM CARES Fund.
From Left to Right: Ms. Neeraja Shetty, CEO and Director, Sami Labs; Dr. Muhammed Majeed, Founder and Chairman, Sami-Sabinsa Group; Dr. Anju Majeed, Director and Sr. Scientist, Sami Labs; and Shaheen Majeed, President Worldwide, Sabinsa and Director, Sami Labs

Sabinsa cosmetics

Material Claiming Naturally High Amounts of Vitamin C IRMS-Tested, Establishing It as Non-Amla, Fermentation Source

Sabinsa, which alerted the industry to synthetic curcumin masquerading as natural source turmeric, has identified mischaracterized amla (Emblica officinalis) extract with claims of high levels of natural vitamin C for sale in the marketplace.

Sabinsa cosmetics

In these uncertain days of the highly contagious coronavirus, the absence of pharmaceutical intervention in the form of drugs or vaccines has pushed scientists to look for clues among safe herbal extract ingredients. A recent peer-reviewed scientific article co-authored by the founder and chairman of Sabinsa, Dr. Muhammed Majeed, along with a galaxy of other scientists, reviews the possible role of curcumin in COVID-19 scenarios with supporting evidence from existing literature.

Sabinsa cosmetics

Two new studies have recently been published on the topical benefits of Sabinsa’s pTeroWhite® natural pterostilbene isolated and purified from Pterocarpus marsupium heartwood and formulated as a cream. The studies further the body of science into pTeroWhite’s value as a cosmeceutical ingredient for anti-aging, skin brightening, and as a natural SPF agent.

Sabinsa cosmetics

Dr. Majeed, Sami-Sabinsa Group’s Founder & Chairman, received the ‘Legend of Natural Cosmeceuticals’ award from Mr. Sandeep Marwah Chancellor, AAFT University of Media & Art and Her Excellency Ms. Jennifer Graham, Spouse of His Excellency Mr. Nadir Patel, Canadian High Commission of India.

Sami-Sabinsa Group, a pioneer and global leader in health science, was honored with three awards by the Associated Chambers of Commerce and Industry of India (ASSOCHAM) at the 3rd edition of their Beauty, Wellness and Personal Care Awards held in New Delhi on February 28, 2020.

Sabinsa cosmetics

Shaheen Majeed, President Worldwide, to speak about sustainability

Sabinsa will demonstrate a delicious next-generation solution for its #1 clinically studied brand of curcumin, Curcumin C3 Complex® as well as highlighting a number of GRAS-affirmed, science-based ingredients from the company’s substantial portfolio at Natural Products Expo West from March 5 – 7, 2020 at the Anaheim Convention Center, Anaheim, CA.

Sabinsa cosmetics

Sami-Sabinsa Group hosted a ground-breaking ceremony, on January 20, 2020, for a new Active Pharmaceutical Ingredients (API) manufacturing unit at Pharma SEZ Industrial Area, Hassan, Karnataka. The latest facility, with a planned investment of $30 Million USD, is part of the group’s strategy to expand existing ingredient growth, and focus on innovative new products. This will be the company’s eighth manufacturing facility.

Sabinsa cosmetics

The award was accepted by Ms. Asha Ramesh, Sabinsa USA’s CEO at an awards ceremony on November 14, 2019.

When the fastest growing 50 companies in New Jersey were announced by NJBIZ, a leading business journal in the state, Sabinsa was pleased to be identified as the 15th of the Fast 50.

Sabinsa cosmetics

Sabinsa has been granted U.S. patent US10166261 for a method of managing dementia and dementia-related sleep disorders presented as symptoms of major depressive disorder (MDD) in humans associated with Irritable Bowel Syndrome (IBS) by administering Bacillus coagulans MTCC 5856 (LactoSpore®) at a dose of 2 billion colony forming units per day. The patent also claims LactoSpore’s ability to reduce serum myeloperoxidase, an essential biochemical marker of MDD.